Investor Relations (IR) Questions: EntreMed ENMD
Click here to return to the biotech IRQ Index
Answers received: October 2012
Our last offering was in the first quarter of this year and was led by IDG/Accel as the lead investor, details of which can be found in our financial reports on our website or through SEC.gov. With the proceeds of the financing, we have started executing our China strategy, including the setup of our new Beijing office. Most recently announced, we have initiated a trial in triple negative breast cancer. Further information can be obtained through our public reports and press releases available on our website. We also look forward to providing further information and guidance to all our shareholders at the soonest appropriate time. Our next financial report is due for filing with the SEC in mid-November.
Thank you for contacting EntreMed.
Our last offering was in the first quarter of this year and was led by IDG/Accel as the lead investor, details of which can be found in our financial reports on our website or through SEC.gov. With the proceeds of the financing, we have started executing our China strategy, including the setup of our new Beijing office. Most recently announced, we have initiated a trial in triple negative breast cancer. Further information can be obtained through our public reports and press releases available on our website. We also look forward to providing further information and guidance to all our shareholders at the soonest appropriate time. Our next financial report is due for filing with the SEC in mid-November.
Thank you for contacting EntreMed.
